| Recruiting | Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumor Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | 2026-03-30 |
| Not Yet Recruiting | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer | Phase 3 | 2026-03-01 |
| Recruiting | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization Wi Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection | Phase 2 | 2026-02-20 |
| Recruiting | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living With HIV -1 Infection | Phase 1 | 2026-02-09 |
| Recruiting | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Pa Recurrent Glioblastoma | Phase 2 | 2026-01-15 |
| Active Not Recruiting | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age COVID-19, SARS-COV-2 Infection | Phase 3 | 2025-12-10 |
| Recruiting | A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined Wi Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | 2025-12-04 |
| Recruiting | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Cancers | Phase 1 / Phase 2 | 2025-11-18 |
| Active Not Recruiting | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of COVID-19, SARS-COV-2 Infection | Phase 3 | 2025-10-30 |
| Recruiting | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer Breast Neoplasms | Phase 3 | 2025-10-30 |
| Recruiting | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentia Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2025-09-22 |
| Recruiting | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination W Advanced Solid Tumor | Phase 1 / Phase 2 | 2025-08-27 |
| Recruiting | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Advanced Solid Tumor | Phase 1 / Phase 2 | 2025-08-12 |
| Recruiting | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another I Metastatic Colorectal Cancer | Phase 1 / Phase 2 | 2025-07-18 |
| Active Not Recruiting | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participa COVID-19, SARS-COV-2 Infection | Phase 3 | 2025-07-08 |
| Withdrawn | A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given Wit Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor | Phase 2 | 2025-07-01 |
| Recruiting | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Rec Endometrial Cancer | Phase 3 | 2025-06-10 |
| Recruiting | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 Advanced Lung Cancer | Phase 1 / Phase 2 | 2025-05-02 |
| Recruiting | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combinati Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer | Phase 1 / Phase 2 | 2025-04-23 |
| Recruiting | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Non-small Cell Lung Cancer | Phase 2 | 2025-03-03 |
| Completed | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People Influenza, COVID-19 (Coronavirus Disease 2019) | Phase 1 / Phase 2 | 2025-02-10 |
| Recruiting | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With U Extensive-stage Small-cell Lung Cancer | Phase 3 | 2025-02-03 |
| Recruiting | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2025-01-13 |
| Recruiting | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Ag Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2025-01-07 |
| Withdrawn | A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children COVID-19 | Phase 1 | 2025-01-06 |
| Completed | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People Influenza,Human, COVID-19 | Phase 1 / Phase 2 | 2024-11-11 |
| Active Not Recruiting | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Co Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers | Phase 2 | 2024-08-26 |
| Active Not Recruiting | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Canc Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | 2024-08-05 |
| Completed | A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multipl Bacterial Vaginosis | Phase 1 | 2024-07-01 |
| Terminated | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Pancreatic Cancer | Phase 1 / Phase 2 | 2024-03-27 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Influenza, COVID-19 | Phase 3 | 2023-12-20 |
| Active Not Recruiting | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors Advanced Malignant Solid Tumor | Phase 1 | 2023-11-30 |
| Completed | A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigation Malaria | Phase 1 / Phase 2 | 2023-11-13 |
| Completed | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeyp Monkeypox | Phase 1 / Phase 2 | 2023-09-21 |
| Completed | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | 2023-08-10 |
| Active Not Recruiting | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis Tuberculosis | Phase 1 / Phase 2 | 2023-07-31 |
| Completed | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis Tuberculosis | Phase 1 | 2023-04-18 |
| Completed | Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria Malaria | Phase 1 | 2022-12-15 |
| Active Not Recruiting | A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Toler Genital Herpes Simplex Type 2 | Phase 1 | 2022-12-08 |
| Completed | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People SARS-CoV-2 Infection, COVID-19 | Phase 1 | 2022-11-08 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates A Influenza, Human, COVID-19 | Phase 2 | 2022-10-28 |
| Active Not Recruiting | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 | Phase 3 | 2022-09-23 |
| Completed | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | 2022-07-26 |
| Recruiting | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combination Non-Small Cell Lung Cancer | Phase 1 | 2022-06-17 |
| Completed | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age SARS-CoV-2 Infection, COVID-19 | Phase 3 | 2022-04-20 |
| Terminated | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2022-03-22 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2022-01-18 |
| Completed | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years SARS-CoV-2 Infection, COVID19 | Phase 2 | 2021-10-15 |
| Completed | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | 2021-08-25 |
| Completed | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162 COVID-19, SARS-CoV-2 Infection | Phase 2 | 2021-07-26 |
| Active Not Recruiting | Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Colorectal Cancer Stage II, Colorectal Cancer Stage III | — | 2021-07-02 |
| Completed | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVI SARS-CoV-2 Infection, COVID-19 | Phase 3 | 2021-07-01 |
| Completed | Dose Escalation Trial of BNT152+153 in Patients With Cancer Solid Tumor | Phase 1 | 2021-06-08 |
| Completed | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma | Phase 2 | 2021-05-19 |
| Completed | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID- SARS-CoV-2 Infection, COVID-19 | Phase 3 | 2021-04-01 |
| Completed | A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Again SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | 2021-03-24 |
| Recruiting | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-p Colorectal Cancer Stage II, Colorectal Cancer Stage III | Phase 2 | 2021-03-08 |
| Completed | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Wome SARS-CoV-2 Infection, COVID-19, Maternal Immunization | Phase 2 / Phase 3 | 2021-02-16 |
| Completed | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose SARS-CoV-2 Infection, COVID-19 | Phase 3 | 2021-02-15 |
| Terminated | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2021-01-26 |
| Recruiting | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 / Phase 3 | 2021-01-07 |
| Completed | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population SARS-CoV-2 | Phase 2 | 2020-12-04 |
| Completed | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in SARS-CoV-2 Infection, COVID-19 | Phase 4 | 2020-10-21 |
| Completed | A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Covid-19, Protection Against COVID-19 | Phase 1 / Phase 2 | 2020-09-09 |
| Completed | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects SARS-CoV-2 | Phase 1 | 2020-07-28 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Solid Tumor, Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | 2020-06-19 |
| Completed | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COV SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | 2020-04-29 |
| Completed | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocom Infections, Respiratory, Virus Diseases, Infection Viral | Phase 1 / Phase 2 | 2020-04-23 |
| Terminated | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) Prostate Cancer | Phase 1 / Phase 2 | 2019-12-19 |
| Completed | RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Phase 1 | 2016-10-01 |
| Completed | Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma | Phase 1 | 2015-03-01 |